|
Compare
Acomplia Rimonabant
Prices Here
|
| Use of Rimonabant |
Rimonabant or Accomplia or Riobant or Slimona or Rimoslim or
Zimulti is the latest selective CB1 cannabinoid receptor blocking
drug formulation introduced by Sanofi-Aventis. In the phase III
clinical trials on smoking cessation treatment as well as
maintaining the self-discipline for weight loss besides controlling
the metabolic disorders linked to being overweight or obese.
Rimonabant is designed to be effectively used as the anti-obesity
drug that precisely acts by blocking the Cannabinoid receptors and
ultimately reduce craving or appetite. For the users in the nations
of the European Union, it is directed to be used in combination with
appropriate diet and exercise plans especially for the patients
having their BMI of over 30kg/cm2 or persons reporting BMI over
27kg/ce and suffer from type 2 diabetes or Dyslipidaemia.
Rimonabant is believed to be greatly helping smokers to give up
their smoking habit. Sanofi-Aventis is actively performing studies
for establishing the positive properties of Rimonabant in regards to
smoking cessation therapy. The specific studies with Rimonabant and
tobacco use called STRATUS program involving over 6,000 persons was
meant for surveying a couple of smoking related therapies. First
using Rimonabant as smoking cessation followed by preventing weight
gain in former smokers. Preliminary reports exhibited positive
results for both the uses.
The U. S. FDA has anyway, not yet granted formal approval of the
drug for smoking cessation therapy to Sanofi-Aventis for selling the
medication within the United States unless required extensive
studies are conducted to establish its efficacy in terms of
anti-smoking properties.
|
|
